STCube Holds Meetings with Multinational Pharmaceutical Companies at BIO USA

[Asia Economy Reporter Hyungsoo Park] Immuno-oncology drug developer STCube announced on the 11th that it will hold partnering meetings for technology licensing with multinational pharmaceutical companies at the ‘2022 BIO International Convention (BIO USA)’ to be held next month.

Hosted by the Biotechnology Innovation Organization (BIO) in the United States, ‘BIO USA’ is the world’s largest bio-industry conference, launched in 1993 and now in its 29th edition. Due to the impact of COVID-19, it will be held offline for the first time in three years since 2019. This year, it will take place from June 13 to 16 in San Diego, USA.

An STCube official explained, "We have received partnering meeting proposals from more than 30 multinational pharmaceutical companies," adding, "We will conduct one-on-one meetings with about 10 companies."

They continued, "We will promote the innovative immuno-oncology drug ‘hSTC810,’ which is currently in Phase 1 clinical trials in the US and Korea, as well as the ‘PD-1/PD-L1’ pipeline in preclinical stages," and added, "We plan to discuss various business models such as technology licensing and joint development partnerships."

STCube held an online corporate briefing session on the 27th of last month, revealing its goal for technology licensing within this year. The company aims to achieve a turnaround to profitability by successfully licensing technology, leveraging the start of the first patient dosing in the Phase 1 clinical trial of hSTC810 as a stepping stone.

STCube’s innovative immune checkpoint inhibitor drug ‘hSTC810’ targets BTN1A1, a member of the Butyrophilin family. The hSTC810 antibody binds to BTN1A1 and blocks the interaction between BTN1A1 and its ligand, thereby activating immune cells. It has a mechanism of action that kills cancer cells through immune activation.

Since it is exclusively expressed with the existing immune checkpoint inhibitor PD-L1, it is evaluated as a new alternative treatment for cancer patients who are unresponsive to existing immune checkpoint inhibitors.

This content was produced with the assistance of AI translation services.